Skip to main content

Table 1 Clinical characteristics of enrolled participants

From: Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B

Variable

Control (152)

AHB (23)

CHB (67)

LC (77)

CSHB (49)

P- value

Female/male

50/102

12/11

18/49

23/54

8/41

0.031

Age (year)

45.1 ± 13.4

40.2 ± 14.9*

39.1 ± 12.2*

50.7 ± 13.4*

44.2 ± 11.8

<0.001

BMI (kg/m2)

22.9 ± 2.9

23.1 ± 2.8

23.1 ± 2.9

22.5 ± 3.3

22.9 ± 3.3

0.237

TBIL (μmol/L)

13.1 ± 4.4

126.9 ± 108.5*

58.5 ± 105.2*

76.6 ± 110.8*

423.5 ± 194.6*

<0.001

TBA (μmol/L)

3 ± 2

133 ± 86*

46 ± 69*

65 ± 76*

156 ± 80*

<0.001

ALT (U/L)

19 ± 9

1289 ± 590*

402 ± 478*

82 ± 165*

309 ± 353*

<0.001

AST (U/L)

19 ± 6

516 ± 398*

190 ± 197*

83 ± 74*

242 ± 203*

<0.001

ChE (U/L)

8364 ± 1521

6003 ± 2012*

6887 ± 2235*

3072 ± 1468*

3477 ± 1370*

<0.001

TG (mmol/L)

0.95 ± 0.33

1.95 ± 0.97*

1.45 ± 0.86*

0.95 ± 0.73*

1.42 ± 0.79*

<0.001

Tch (mmol/L)

4.17 ± 0.58

3.46 ± 0.71*

3.67 ± 0.87*

3.16 ± 1.67*

2.62 ± 1.49*

<0.001

HDL-c (mmol/L)

1.33 ± 0.24

0.42 ± 0.41*

0.86 ± 0.45*

0.67 ± 0.45*

0.11 ± 0.15*

<0.001

LDL-c (mmol/L)

2.41 ± 0.47

1.46 ± 0.94*

1.90 ± 0.68*

1.64 ± 0.71*

1.09 ± 0.87*

<0.001

apoAI (g/L)

1.18 ± 0.25

0.61 ± 0.35*

0.95 ± 0.38*

0.64 ± 0.30*

0.21 ± 0.16*

<0.001

apoB (g/L)

0.69 ± 0.15

0.87 ± 0.27*

0.74 ± 0.24*

0.57 ± 0.25*

0.71 ± 0.33*

<0.001

Cr (μmol/L)

71 ± 13

99 ± 156*

74 ± 17

80 ± 69

102 ± 77*

0.111

Glu (mmol/L)

4.76 ± 0.41

4.79 ± 0.81

4.79 ± 0.85

5.45 ± 2.42*

4.86 ± 2.53

0.052

PT (s)

-

12.7 ± 1.48

12.2 ± 2.59

16.3 ± 5.2

23.5 ± 9.6

<0.001#

PAF-AH (U/L)

450 ± 125

872 ± 355*

614 ± 315*

666 ± 267*

1320 ± 481*

<0.001

MELD score

-

11.9 ± 5.9

6.9 ± 5.7

10.7 ± 7.0

24.7 ± 9.1

<0.001#

Mortality (yes/no)

-

0/23

0/67

7/70

27/22

<0.001#

  1. AHB: acute hepatitis B; CHB, chronic hepatitis B; LC, liver cirrhosis; CSHB, chronic severe hepatitis B; Cr, creatinine; PT, prothrombin time.
  2. P-value: comparison among these five groups. #comparison among these four groups. *P < 0.05 vs. the control group.